background
viral
respiratori
infect
associ
wheez
episod
asthma
exacerb
howev
studi
role
virus
asthmat
patient
interv
exacerb
spars
studi
aim
determin
presenc
respiratori
virus
without
symptom
infect
airway
young
asthmat
compar
healthi
control
materi
method
patient
year
age
stabl
asthma
group
healthi
control
analyz
regard
presenc
rna
common
respiratori
virus
nasopharyng
aspir
pcr
selfreport
asthma
control
qualiti
life
fraction
exhal
nitric
oxid
feno
spirometri
bronchial
respons
methacholin
record
blood
sampl
collect
assess
ige
sensitis
eosinophil
cation
protein
ecp
level
result
patient
asthma
healthi
control
human
rhinoviru
hrv
viru
detect
asthmat
vs
control
p
hrv
asthma
patient
higher
degre
aeroallergen
ige
sensitis
median
vs
ku
l
p
tendenc
higher
level
serum
ecp
median
vs
mgl
p
compar
hrv
counterpart
conclus
absenc
symptom
respiratori
tract
infect
notwithstand
hrv
seem
preval
airway
adolesc
young
adult
asthma
high
degre
aeroallergen
ige
sensitis
control
presenc
hrv
seem
also
relat
system
eosinophil
inflamm
despit
ongo
treatment
inhal
corticosteroid
viral
respiratori
infect
associ
wheez
episod
asthma
exacerb
children
adult
increas
rate
hospit
admiss
asthma
higher
detect
rate
respiratori
virus
report
coincid
howev
regard
role
respiratori
virus
asthmat
patient
stabl
period
exacerb
littl
data
avail
specul
human
rhinoviru
hrv
abil
caus
persist
infect
patient
asthma
small
studi
suggest
preponder
respiratori
virus
nonexacerb
asthmat
individu
compar
healthi
control
viral
load
clinic
deterior
acut
hrv
infect
shown
relat
reduc
interferon
respons
increas
type
interleukin
il
respons
patient
asthma
compar
nonasthmat
control
human
airway
epitheli
cell
produc
proinflammatori
molecul
cxc
motif
chemokin
relat
hrv
infect
respons
appear
specif
viralinduc
acut
asthma
moreov
cytokin
increas
releas
presenc
rhinoviru
infect
thu
inflamm
airway
could
possibl
facilit
viral
replic
prolong
period
vice
versa
infect
could
promot
chronic
airway
inflamm
environ
inflamm
airway
induc
nitric
oxid
synthas
upregul
respiratori
epithelium
fraction
exhal
nitric
oxid
feno
consequ
increas
furthermor
inflamm
characteris
eosinophil
recruit
viral
infect
seem
caus
system
activ
eosinophil
least
subject
allerg
asthma
elucid
possibl
role
persist
viru
infect
conduct
larg
crosssect
studi
young
patient
asthma
n
match
control
n
mida
cohort
without
symptom
respiratori
tract
infect
end
preval
hrv
respiratori
syncyti
viru
rsv
influenza
virus
b
human
coronaviru
hcov
known
associ
asthma
exacerb
examin
nasopharyng
aspir
npa
asthmat
control
compar
secondari
aim
see
presenc
respiratori
virus
relat
biomark
inflamm
andor
allerg
sensitis
studi
base
mida
cohort
detail
method
publish
elsewher
total
patient
year
age
physiciandiagnos
asthma
report
medic
record
well
daili
treatment
inhal
corticosteroid
ic
andor
oral
leukotrienereceptor
antagonist
ltra
least
three
month
year
examin
includ
studi
subject
interview
examin
sampl
stabl
state
asthma
e
exacerb
within
past
two
week
refrain
take
asthma
allergi
medic
h
studi
total
healthi
subject
without
diagnosi
respiratori
diseas
randomli
chosen
uppsala
popul
regist
sweden
sexand
agematch
asthma
patient
particip
control
subject
told
free
symptom
respiratori
tract
infect
cough
sore
throat
runni
nose
sneez
nasal
congest
pink
eye
fever
least
two
week
day
examin
subject
inclusionexclus
flow
chart
shown
fig
subject
asthma
fill
asthma
control
test
act
junip
mini
asthmarel
qualiti
life
questionnair
maqlq
order
assess
degre
asthma
control
asthmarel
qualiti
life
respect
dynam
spirometri
perform
use
masterscop
spiromet
erich
jager
wurzburg
germani
methacholin
challeng
test
perform
use
aerosol
provoc
system
viasi
healthcar
gmbh
hoechberg
germani
exhal
measur
accord
atser
recommend
use
chemiluminesc
analys
niox
flex
aerocrin
ab
solna
sweden
npa
collect
previous
describ
store
c
total
viral
nucleic
acid
extract
qiaamp
minelut
viru
spin
kit
qiagen
usa
accord
manufactur
protocol
ml
npa
elut
ml
extract
realtim
pcr
assay
detect
hrv
includ
speci
b
c
hcov
influenza
b
rsv
perform
abi
realtim
pcr
system
appli
biosystem
plasmid
viral
rna
use
posit
control
venou
blood
sampl
drawn
blood
cell
count
prepar
serum
plasma
edta
sampl
store
c
serum
blood
allow
clot
min
c
blood
leukocyt
count
determin
use
routin
method
celldyn
sapphir
abbott
il
usa
depart
clinic
chemistri
uppsala
univers
hospit
measur
ige
antibodi
mix
aeroallergen
phadiatop
cat
dog
hors
dermatophagoid
pteronyssinu
dermatophagoid
farina
cladosporium
herbarum
birch
timothi
grass
mugwort
food
allergen
egg
white
milk
cod
fish
wheat
peanut
soybean
perform
subject
identifi
atop
phadiatop
ku
l
ige
antibodi
total
ige
serum
eosinophil
cation
protein
secp
measur
use
immunocap
system
thermo
fisher
scientif
uppsala
sweden
cxc
motif
chemokin
measur
sandwich
elisa
r
system
minneapoli
mn
usa
measur
perform
hrv
asthmat
n
hrv
asthmat
match
sex
age
atopi
femal
vs
p
age
mean
sd
vs
year
p
atopi
vs
p
chisquar
test
use
compar
proport
nonparametr
statist
use
whole
studi
due
low
number
case
hrv
subject
mannwhitney
u
test
use
compar
median
continu
variabl
multipl
logist
regress
model
creat
confirm
effect
risk
factor
hrv
posit
adjust
confound
factor
stata
ic
statacorp
lp
colleg
station
texa
usa
use
statist
analys
region
ethic
committe
uppsala
approv
studi
reg
subject
appropri
legal
guardian
gave
written
inform
consent
subject
characterist
present
tabl
patient
asthma
differ
healthi
control
regard
lung
function
level
biomark
ige
sensitis
slightli
larger
proport
asthmat
recruit
summer
juneeaugust
compar
control
fig
proport
asthmat
recruit
common
cold
season
marchmay
septembernovemb
lower
control
differ
signific
vs
p
smaller
proport
asthmat
report
cigarett
smoke
compar
control
fig
hcov
rsv
influenza
b
found
subject
howev
hrv
found
total
subject
uneven
distribut
group
asthmat
one
healthi
control
fig
result
preval
subject
asthma
control
p
furthermor
presenc
hrv
unevenli
distribut
season
thirteen
hrv
subject
sampl
marchmay
septembernovemb
fig
differ
regard
sex
bmi
hrv
n
hrv
n
asthmat
tabl
howev
hrv
patient
tend
older
vs
year
p
smoke
vs
p
hrv
differ
regard
lung
function
bronchial
respons
use
antiinflammatori
asthma
medic
asthma
control
asthmarel
qualiti
life
could
detect
two
group
asthmat
tabl
biomark
blood
leukocyt
count
ige
sensitis
hrv
vs
hrv
patient
asthma
hrv
patient
asthma
higher
feno
compar
hrv
counterpart
reach
signific
vs
ppb
p
tabl
secp
show
statist
trend
toward
elev
level
hrv
subject
vs
mgl
p
wherea
blood
eosinophil
count
differ
group
tabl
also
trend
toward
statist
tabl
characterist
studi
subject
present
median
iqr
signific
increas
neutrophil
vs
l
p
monocyt
vs
p
absolut
count
hrv
asthmat
tabl
analys
differenti
cell
count
percentag
total
leukocyt
count
comparison
nonsignific
p
interestingli
hrv
asthmat
characteris
greater
degre
ige
sensitis
aeroallergen
compar
hrv
patient
vs
kul
p
tabl
result
confirm
atop
asthmat
n
includ
analysi
iqr
kul
hrv
n
vs
iqr
kul
hrv
subject
n
p
degre
ige
sensitis
food
allergen
total
ige
differ
group
tabl
multipl
logist
regress
model
includ
subject
asthma
associ
degre
aeroallergen
ige
sensitis
hrv
posit
consist
p
adjust
age
sex
height
weight
fev
current
smoke
higher
age
p
also
signific
determin
model
similar
analysi
subject
atop
asthma
yield
similar
result
degre
ige
sensitis
aeroallergen
p
higher
age
p
male
sex
p
signific
crosssect
studi
detect
higher
frequenc
hrv
upper
respiratori
tract
young
subject
asthma
without
ongo
recent
symptom
respiratori
tract
infect
compar
healthi
control
contrast
rsv
influenza
b
hcov
rna
detect
subject
hrv
asthmat
subject
characteris
higher
degre
aeroallergen
ige
sensitis
higher
level
secp
hrv
subject
wherea
blood
eosinophil
feno
asthma
control
asthmarel
qualiti
life
differ
studi
assess
preval
common
respiratori
tract
virus
larg
number
asymptomat
asthmat
patient
collect
yearround
compar
ageand
sexmatch
healthi
control
although
preval
hrv
higher
asthmat
patient
studi
differ
show
trend
toward
statist
signific
howev
slightli
larger
proport
asthmat
subject
examin
outsid
common
cold
season
may
reduc
chanc
find
hrv
asthmat
rel
control
furthermor
differ
hrv
preval
group
seen
spite
fact
significantli
larger
proport
control
subject
asthmat
smoker
factor
may
increas
suscept
hrv
infect
accordingli
trend
toward
higher
preval
smoker
hrv
asthmat
versu
hrv
asthmat
studi
cigarett
smoke
shown
downregul
bronchial
epitheli
releas
antivir
protein
exampl
respons
rhinoviru
infect
via
inhibit
multipl
transcript
pathway
link
innat
immun
respons
wo
colleagu
previous
demonstr
hrv
detect
lower
respiratori
tract
asthmat
patient
frequent
healthi
control
absenc
recent
asthma
exacerb
sign
common
cold
howev
asthmat
subject
studi
undergon
bronchoscopi
clinic
indic
thu
repres
gener
asthma
popul
small
studi
schoolchildren
symptomfre
period
indic
greater
preval
hrv
asthmat
compar
control
children
statist
comparison
group
present
time
year
sampl
describ
contrast
recent
rel
larg
studi
show
similar
preval
hrv
children
stabl
asthma
healthi
control
nordic
countri
symptomat
hrv
infect
occur
yearround
peak
spring
fall
line
asymptomat
hrv
infect
detect
marchmay
septembernovemb
indic
may
detect
subacut
infect
rather
shed
persist
infect
crosssect
studi
design
prevent
analysi
presenc
chronic
hrv
infect
shed
among
asthmat
one
could
specul
true
preval
detect
hrv
higher
well
evenli
distribut
season
furthermor
jartti
et
al
recent
show
infant
prolong
recurr
respiratori
ill
often
seri
infect
rather
persist
infect
one
viru
strain
howev
given
hrv
detect
consecut
sampl
longitudin
studi
shortterm
persist
slower
clearanc
rhinoviru
also
possibl
studi
sotoquiro
cowork
schoolchildren
stabl
asthma
hrv
inclus
primarili
done
common
cold
season
wherea
recruit
yearround
could
explain
higher
hrv
preval
compar
studi
frequenc
hrv
infect
rather
high
preschool
children
decreas
age
parent
young
children
howev
seem
catch
cold
primarili
home
hiatu
decreas
hrv
frequenc
observ
age
interv
year
coincid
time
peopl
commonli
establish
famili
could
possibl
explain
found
median
age
hrv
asthmat
patient
year
wherea
hrv
patient
year
lack
detect
viral
rna
rsv
influenza
b
hcov
consist
two
studi
asymptomat
asthmat
individu
data
support
uniqu
relationship
asthma
suscept
hrv
infect
hrv
asthma
patient
show
higher
degre
ige
sensitis
aeroallergen
compar
hrv
asthmat
wherea
hrv
posit
relat
food
allergen
sensitis
would
line
previous
shown
relationship
suscept
hrv
infect
local
increas
type
cytokin
atopi
per
se
exhal
signal
local
cytokin
activ
airway
mean
feno
increas
hrv
asthmat
reach
signific
howev
must
note
asthmat
studi
use
inhal
corticosteroid
feno
often
rapidli
reduc
treatment
wherea
restor
viral
host
defenc
may
slower
process
exhal
also
increas
hrv
infect
increas
seen
day
acut
infect
thu
influenc
result
studi
also
show
serum
level
ecp
tend
elev
hrv
asthmat
wherea
beo
count
instead
trend
toward
increas
number
blood
neutrophil
monocyt
seen
hrv
subject
previou
studi
shown
increas
neutrophil
count
induc
sputum
viru
infect
asthmat
control
jarjour
et
al
shown
increas
beo
differenti
count
acut
hrv
inocul
patient
atop
asthma
wo
et
al
present
increas
beo
count
atop
asthmat
asymptomat
hrv
posit
lower
airway
one
studi
show
increas
secp
acut
hrv
exposur
patient
atop
asthma
high
ige
concentr
elev
secp
beo
count
associ
acut
virusinduc
exacerb
children
indic
secp
may
sensit
marker
hrvinduc
system
eosinophil
activ
beo
count
plasma
level
previous
shown
increas
acut
asthma
presum
relat
hrv
infect
wherea
elev
stabl
asthma
could
detect
increas
plasma
level
asymptomat
hrv
asthmat
studi
indic
low
rate
viru
replic
subject
limit
studi
may
perform
followup
examin
thu
data
allow
us
determin
whether
increas
preval
subclin
hrv
infect
asthmat
relat
increas
frequenc
acut
infect
slower
elimin
viru
acut
infect
selfreport
symptom
increas
risk
bia
may
sampl
individu
incub
phase
acut
hrv
infect
howev
incub
time
short
hrv
shorter
respiratori
virus
suggest
risk
low
anoth
potenti
limit
diagnos
hrv
speci
patient
infect
regard
hrv
posit
effect
level
feno
recent
report
show
differ
hrv
speci
also
crosssect
studi
allow
prospect
assess
upcom
asthma
exacerb
conclus
hrv
rsv
influenza
ab
hcov
detect
airway
asthmat
free
symptom
infect
least
two
week
preval
hrv
tend
increas
adolesc
young
adult
asthma
compar
agematch
control
presenc
hrv
asthmat
significantli
associ
degre
ige
sensitis
aeroallergen
weakli
secp
level
data
suggest
hrv
infect
common
andor
clear
slower
rate
asthmat
sign
high
degre
diseas
compar
healthi
control
differ
seem
relat
presenc
system
eosinophil
inflamm
despit
inhal
corticosteroid
treatment
mida
studi
financi
support
within
framework
academyindustri
collabor
initi
swedish
government
agenc
innov
system
vinnova
sambio
program
grant
number
aerocrin
ab
thermo
fisher
scientif
immunodiagnost
partner
cofinanc
program
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
fund
also
receiv
swedish
heartlung
foundat
swedish
asthma
allergi
associ
research
foundat
ka
receiv
research
support
thermo
fisher
scientif
aerocrin
author
declar
compet
interest
exist
